3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
4
Sarcoma
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Advanced Pancreatic Cancer
1
Interventions
Doxorubicin
33
Ifosfamide
23
Gemcitabine
19
pazopanib
18
Cyclophosphamide
16
Radiotherapy
15
pembrolizumab
13
Filgrastim
12
Docetaxel
12
Bevacizumab
10
Vincristine
9
Sirolimus
9
Irinotecan
9
Etoposide
9
olaratumab
7
eribulin
7
Sorafenib
7
Radiation
7
temsirolimus
6
Temozolomide
6
Mesna
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
tazemetostat
5
cixutumumab
5
Trabectedin
5
Radiosurgery
5
Nivolumab
5
Ipilimumab
5
Granulocyte Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Sarcoma
×
IMM-101
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts